Supernus Pharmaceuticals reported $173.43M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Aerie Pharmaceuticals AERI:US $ 39.44M 17M
Ani Pharmaceuticals ANIP:US $ 76.91M 23.39M
Aurora Cannabis Inc ACB:CN 429.89M 97.49M
Bristol Myers Squibb BMY:US $ 10750M 1619M
Canopy Growth Corp WEED:CN C$ 769.5M 464.17M
Cara Therapeutics CARA:US $ 21.36M 7.91M
Corcept Therapeutics CORT:US $ 35.35M 26.52M
Eisai 4523:JP Y 287815M 23426M
Eli Lilly And LLY:US $ 2622.9M 163.7M
Endo International Ordinary Shares ENDP:US $ 1413.15M 94.05M
Horizon Pharma HZNP:US $ 1892.56M 249.43M
Lannett LCI:US $ 106.11M 7.47M
Marinus Pharmaceuticals MRNS:US $ 126.32M 3.39M
Pacira Pharmaceuticals PCRX:US $ 122.06M 104.69M
Perrigo Ordinary Shares PRGO:US $ 1965.5M 100.6M
Revance Therapeutics RVNC:US $ 198.36M 87.74M
Supernus Pharmaceuticals SUPN:US $ 173.43M 57.71M
Teva Pharmaceutical Industries TEVA:US $ 2058M 117M
United Therapeutics UTHR:US $ 795.2M 18.1M
Xeris Pharmaceuticals Inc XERS:US $ 103.77M 36.5M